Nektar Therapeutics (NKTR) Shares are Down -8.37%

Nektar Therapeutics (NKTR) : During the past 4 weeks, traders have been relatively bearish on Nektar Therapeutics (NKTR), hence the stock is down -6.38% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -8.52% relative to the S&P 500. The 4-week change in the price of the stock is -6.88% and the stock has fallen -8.37% in the past 1 week.

The stock has recorded a 20-day Moving Average of 8.19% and the 50-Day Moving Average is 3.07%.The 200 Day SMA reached 13.94%


Nektar Therapeutics (NASDAQ:NKTR): After opening at $17.06, the stock dipped to an intraday low of $16.76 on Friday. However, the bulls stepped in to buy at lower levels and pushed the stock higher. The stock touched an intraday high of $17.42 and the buying power remained strong till the end. The stock closed at $17.18 for the day, a gain of 1.36% for the day session. The total traded volume was 1,269,349. The stocks close on the previous trading day was $17.18.

Nektar Therapeutics (NKTR) : The highest level Nektar Therapeutics (NKTR) is projected to reach is $25 for the short term and the lowest estimate is at $14. The consolidated price target from 7 rating analysts who initiate coverage on the stock is $19.86 and the possibility the share price can swing is $3.53.

Nektar Therapeutics is a clinical-stage biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action. The Companys pipeline is comprised of drug candidates for therapeutic areas, including oncology, pain, anti-infectives, and immunology. The Companys research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. Its polymer chemistry platform is being used to create specialized therapeutics, including small molecule oral and parenteral drugs, proteins, peptides and antibody fragments.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *